Please login to the form below
AMD
This page shows the latest AMD news and features for those working in and with pharma, biotech and healthcare.
Novartis stumbles in Q2 as COVID-19 impacts sales
That includes its wet AMD drug Lucentis (ranibizumab), which fell 25% to bring in $401m in the quarter.
Latest news
-
Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD
Beovu (brolucizumab) is the first anti-VEGF treatment to demonstrate superior resolution of retinal fluid compared to Eylea (aflibercept) in patients with wet age-related macular degeneration (AMD), according to Novartis. ... aflibercept) squaring off
-
Novartis highlights emerging assets and late-stage pipeline at R&D day
It also has plans to expand wet AMD therapy Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments Piqray (alpelisib) and Kisqali(ribociclib) into additional indications to help drive growth.
-
Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture
s Eylea (aflibercept), which together account for the lion’s share of the wet AMD market by value. ... Lucentis was the first VEGF inhibitor to reach the market for wet AMD and grew quickly into a blockbuster product with sales of around $3.7bn last
-
Novartis bags US okay for Lucentis follow-up Beovu in wet AMD
The green light for Beovu (brolucizumab) is a boost for Novartis as it tries to defend its wet AMD franchise, currently represented by $2bn-plus VEGF inhibitor product Lucentis (ranibizumab) which ... Novartis’ drug was the first VEGF inhibitor to
-
Life sciences and NHS feature in Johnson speech – but Brexit promises predominate
This was an apparent reference to Gyroscope, the company based in the Stevenage biotech cluster near London, which is testing its gene therapy for advanced dry Age-related Macular Degeneration (AMD).
More from news
Approximately 26 fully matching, plus 75 partially matching documents found.
Latest Intelligence
-
25 Women Leaders in UK Healthcare (part 2)
for advanced dry Age-related Macular Degeneration (AMD).
-
Deal Watch October 2018
RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry Age-related Macular Degeneration (AMD). ... Effectively the deal is structured as an option, as the phase 2 study in dry AMD will be
-
30 Women Leaders in UK Healthcare (part 2)
treatments for age-related macular degeneration (AMD).
-
The good, the bad and the ugly
In the EU, where there’s a high prevalence of AMD, Bayer has enjoyed great success with Eylea - growing revenues by 18% in 2017,” says Alice Stevens, analyst, cardiovascular and metabolic ... The company plans to launch the highly anticipated
-
Working with our healthcare system more closely is vital
to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD).
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Gyroscope Therapeutics appoints CEO
Gyroscope has a unique translational approach to tackling complex diseases such as dry AMD for which there are no therapies today.”.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gilead agrees $21bn buyout of Immunomedics
- New medical communications agency BOLDSCIENCE launches
- Moderna inks R&D agreements with Vertex and Chiesi
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- FDA approves Roche’s Actemra COVID-19 trial
- OPEN Health’s Digital team have won a Bronze Award at the PM Society Digital Awards 2020
- New restrictions announced as UK’s COVID-19 alert level is increased
- Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer
- AZ/Merck's Lynparza improves survival in certain prostate cancers
- The flexible salesforce
- Navigating engagement and remote working during the pandemic
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
Quick links
Infographics
